{"denoms":[{"counts":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"39"},{"groupId":"BG004","value":"132"},{"groupId":"BG005","value":"297"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"BG000","title":"Cohort A: Triple Negative Breast Cancer"},{"description":"Participants received pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"BG001","title":"Cohort B: Head & Neck Cancer"},{"description":"Participants received pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"BG002","title":"Cohort C: Urothelial Cancer"},{"description":"Participants received pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"BG003","title":"Cohort D: Gastric Cancer"},{"description":"Participants received pembrolizumab, 200 mg, IV once every 3 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"BG004","title":"Cohort B2: Head & Neck Cancer Expansion"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.1","value":"51.9"},{"groupId":"BG001","spread":"11.5","value":"61.5"},{"groupId":"BG002","spread":"10.3","value":"68.5"},{"groupId":"BG003","spread":"13.2","value":"58.3"},{"groupId":"BG004","spread":"9.7","value":"58.9"},{"groupId":"BG005","spread":"11.6","value":"59.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"22"},{"groupId":"BG005","value":"87"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"110"},{"groupId":"BG005","value":"210"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"12"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"37"},{"groupId":"BG004","value":"108"},{"groupId":"BG005","value":"255"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"30"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"28"},{"groupId":"BG005","value":"48"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"19"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"95"},{"groupId":"BG005","value":"223"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"The baseline analysis population consisted of all allocated participants."}